- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02420678
Quality of Life in Patients With Hepatocellular Carcinoma
Validation of Questionnaire Module for Quality of Life and Analysis of Its Association With Clinical Outcomes; a Cohort Study in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading cause of cancer-related mortality worldwide. Despite the recent advances in the treatment of HCC, the prognosis of HCC is still poor even after curative treatment.
Performance status has shown to be associated with long-term survival and prognosis in patients with HCC, and it is one of the important factors in the Barcelona Clinic Liver Cancer (BCLC) staging system. Recently, the researches on health-related quality of life (HRQL) of cancer patients have been progressed. The most widely used surveys to assess HRQL of cancer patients are Functional Assessment of Cancer Therapy-Generic (FACT-G) and European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30. Since those two are mainly about cancers in general, HCC specific surveys were developed.
The FACT-Hep questionnaire has 45-items specifically focusing on patients with hepatobiliary cancers. EORTC QLQ-hepatocellular carcinoma 18 (HCC 18) is an 18-item questionnaire designed to be used along with the EORTC QLQ-C30 for patients with HCC. An 18-item National Comprehensive Cancer Network (NCCN)-FACT Hepatobiliary-Pancreatic Symptom Index (NFHSI-18) is a specific questionnaire for advanced hepatobiliary and pancreatic cancers. However, there is no consensus whether it would be appropriate to adopt HRQL as a prognostic variable in HCC staging system. Moreover, there is limited information available about the impact of patients' HRQL on long-term outcome in patients with HCC.
Thus, in this study, the researchers will investigate whether HRQL can be an important factor in HCC staging system by testing the reliability and clinical validity of FACT-Hep, EORTC QLQ-HCC18, and NFHSI-18. Second, the investigators will evaluate the relation of HRQL with treatment efficacy, recurrence and survival outcome. Lastly, the investigators will suggest the suitable questionnaire module for patients with HCC.
연구 개요
상태
정황
연구 유형
등록 (예상)
연락처 및 위치
연구 장소
-
-
-
Seoul, 대한민국, 138-736
- 모병
- Asan Medical Center
-
연락하다:
- Ju Hyun Shim, MD, PhD
- 전화번호: +82-2-3010-3190
- 이메일: s5854@medimail.co.kr
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- 18 years of age or older
- Diagnosis of HCC
- Ability to speak, read, and write Korean
- Patient is able and willing to give informed consent
Exclusion Criteria:
- Evidence of cognitive impairment or psychiatric disturbance
- Other concurrent malignancy
- Patients involved in other clinical studies
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Clinical validity of FACT-Hep, EORTC QLQ-HCC18 and NFHSI-18
기간: Baseline
|
The FACT-Hep questionnaire consists of 18-item Hepatobiliary Subscales and 27-item FACT-G, which contains physical (7 items), social (7 items), emotional (6 items), and functional scales (7 items).
Hepatobiliary Subscale is scored 0-72, FACT-G is scored 0-108, and FACT-Hep is scored 0-180.
EORTC QLQ-HCC 18 is an 18-item questionnaire designed to be used along with the 30-item EORTC QLQ-C30.
EORTC QLQ-HCC 18 questionnaire includes 8 symptom scales such as fatigue, jaundice, nutrition, pain, fever, abdominal swelling, sexual interest, and body image.
Each item is scored 0-100 according to the EORTC guidelines.
NFHSI-18 consists of 18-item scales, and each item is scored 0-4, yielding a total between 0 and 72.
The investigators will test the validity by using the correlation and comparison of all of the questionnaire scores at baseline.
|
Baseline
|
Reliability of FACT-Hep, EORTC QLQ-HCC18 and NFHSI-18
기간: Baseline and at least 6 hours later
|
Patients will complete the questionnaires at baseline and then will respond to the follow-up surveys at least 6 hours later the first assessment.
The investigators will examine reliability by assessing test-retest reliability of each survey after measuring the scores of questionnaires at two assessment points.
|
Baseline and at least 6 hours later
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Recurrence rates
기간: upto 3 years
|
upto 3 years
|
Death rates
기간: upto 3 years
|
upto 3 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Ju Hyun Shim, MD, PhD, Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .